Estimates Revisions Perspective Therapeutics, Inc.
Stocks
CATX
US46489V3024
Biotechnology & Medical Research
|
Delayed
NYSE
16:00:00 2026-09-04 EDT
|
5-day change | 1st Jan Change | ||
| 3.130 USD | +0.32% |
|
+0.64% | +13.82% |
| 08-19 | BMO Capital Initiates Perspective Therapeutics at Outperform | MT |
| 08-14 | BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6 | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- CATX Stock
- Consensus Perspective Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
